Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.75
Nov 16 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Nov 16, 10:02 AMFriday Q3 EsoGuard Medicare news extends PAVmed rally 21% Monday
Index
-
Market Cap
13.99M
Enterprise Value
4.97M
Income
-26.05M
Sales
0.15M
Book/sh
4.98
Cash/sh
1.78
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
41
IPO
Apr 28, 2016
P/E
-
Forward P/E
-
PEG
-
P/S
93.27
P/B
0.35
P/C
0.99
P/FCF
-
EV/EBITDA
-
EV/Sales
33.13
Quick Ratio
1.19
Current Ratio
1.19
Debt/Eq
0.49
LT Debt/Eq
0.47
Option/Short
No / Yes
EPS (ttm)
-9.43
EPS next Y
-1.98
EPS next Q
-0.56
EPS this Y
35.70%
EPS next Y
45.30%
EPS next 5Y
-
EPS past 3/5Y
76.80% 55.65%
Sales past 3/5Y
-42.68% -
EPS Y/Y TTM
-185.92%
Sales Y/Y TTM
410.34%
EPS Q/Q
79.90%
Sales Q/Q
720.00%
Insider Own
48.12%
Insider Trans
0.00%
Inst Own
17.87%
Inst Trans
25.75%
ROA
-28.75%
ROE
-31.88%
ROIC
-38.30%
Gross Margin
-220.27%
Oper. Margin
-19315.54%
Profit Margin
-17602.03%
SMA20
-5.33%
SMA50
-37.42%
SMA200
-71.70%
Trades
Shs Outstand
8.00M
Shs Float
4.15M
52W High
28.44 -93.85%
52W Low
1.17 49.57%
Volatility
28.98% 15.25%
ATR (14)
0.29
RSI (14)
39.37
Beta
0.89
Rel Volume
0.00
Avg Volume
22.90K
Volume
0
Perf Week
7.36%
Perf Month
-27.39%
Perf Quarter
-65.42%
Perf Half Y
-71.82%
Perf YTD
-73.58%
Perf Year
-81.77%
Perf 3Y
-97.96%
Perf 5Y
-99.91%
Perf 10Y
-99.95%
Prev Close
1.75
Price
1.75
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$36.50
Implied Upside
+1,985.7%
Analysts3incl. previous ratings
Rating Distribution3 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 30, 2021Initiated
CCantor Fitzgerald
Overweight$8+357.1%
Nov 05, 2020Initiated
AAscendiant Capital Markets
Buy$5+185.7%
Jun 28, 2018Initiated
MMaxim Group
Buy$5+185.7%
PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.
Chairman & CEODr. Lishan Aklog M.D.
President & CFOMr. Dennis M. McGrath CPA
Executive VP & COOMr. Shaun M. O'Neill M.B.A.
Executive VPMr. Michael Adam Gordon
Executive VPDr. Brian J. deGuzman M.D.